HSR&D Citation Abstract
Search | Search by Center | Search by Source | Keywords in Title
Variation in Statin Prescription among Veterans with HIV and Known Atherosclerotic Cardiovascular Disease.
Erqou S, Papaila A, Halladay C, Ge A, Liu MA, Jiang L, Lally M, Menon A, Shah NR, Miech E, Virani SS, Zullo AR, Shireman TI, Longenecker CT, Ross D, Sullivan JL, Wu WC, Rudolph JL. Variation in Statin Prescription among Veterans with HIV and Known Atherosclerotic Cardiovascular Disease. American heart journal. 2022 Mar 19.
People with HIV have increased atherosclerotic cardiovascular disease (ASCVD) risk, worse outcomes following incident ASCVD, and experience gaps in cardiovascular care, highlighting the need to improve delivery of preventive therapies in this population.
Identify patient-level correlates and inter-facility variation in statin prescription among Veterans with HIV and known ASCVD.
We studied Veterans with HIV and existing ASCVD, i.e., coronary artery disease (CAD), ischemic cerebrovascular disease (ICVD), and peripheral arterial disease (PAD), who received care across 130 VA medical centers for the years 2018-2019. We assessed correlates of statin prescription using two-level hierarchical multivariable logistic regression. Median odds ratios (MORs) were used to quantify inter-facility variation in statin prescription.
9608 Veterans with HIV and known ASCVD (mean age 64.3 ± 8.9 years, 97% male, 48% Black) were included. Only 68% of the participants were prescribed any-statin. Substantially higher statin prescription was observed for those with diabetes (adjusted odds ratio [OR]? = 2.3, 95% confidence interval [CI], 2.0-2.6), history of coronary revascularization (OR? = 4.0, CI, 3.2-5.0), and receiving antiretroviral therapy (OR? = 3.0, CI, 2.7-3.4). Blacks (OR? = 0.7, CI, 0.6-0.9), those with noncoronary ASCVD, i.e., ICVD and/or PAD only, (OR 0.53, 95% CI: 0.48-0.57), and those with history of illicit substance use (OR = 0.7, CI, 0.6-0.9) were less likely to be prescribed statins. There was significant variation in statin prescription across VA facilities (10th, 90th centile: 55%, 78%), with an estimated 20% higher likelihood of difference in statin prescription practice for two clinically similar individuals treated at two comparable facilities (adjusted MOR? = 1.21, CI, 1.18-1.24), and a greater variation observed for Blacks or those with noncoronary ASCVD or history of illicit drug use.
In an analysis of large-scale VA data, we found suboptimal statin prescription and significant interfacility variation in statin prescription among Veterans with HIV and known ASCVD, particularly among Blacks and those with history noncoronary ASCVD.